NCT01884051Recruiting
Hormonal, Metabolic, and Signaling Interactions in PAH
Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1899 (estimated)
- First submitted
- 15 Jan 2013
- Start date
- Sept 2012
- Primary completion date
- Jul 2032
- Lead sponsor
- Vanderbilt University Medical Center
- NCT number
- NCT01884051
What you commit to
- Study type: Observational
- Planned participants: 1899
- From Sept 2012 to the primary completion date, Jul 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Project 1
- Inclusion:
- Diagnosis of IPAH (idiopathic pulmonary arterial hypertension), HPAH (heritable pulmonary arterial hypertension), or APAH (associated pulmonary arterial hypertension), family members of affected persons
- Age 0-90, age 12-90 for skin biopsy
- Exclusion:
- Other diagnosis
- Age greater than 90, age less than 12 or greater than 90 for skin biopsy
- Project 2
- Inclusion:
- Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
- 0-90
- Subjects with reasonably easy access to clinic for blood collection and other testing
- Subject able to tolerate fasting state prior to sample collection and EndoPAT (endothelial function assessment) testing
- Exclusion:
- Other diagnosis
- 0-90
- Subjects with difficulty reaching clinic for blood collection and other testing
- Subjects unable to tolerate fasting state
- Project 3
- Inclusion:
- Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
- 7-90
- Exclusion:
- Other diagnosis
- Age less than 7 or greater than 90
- \-
Age in the registry: - to 90 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
Related publications
- Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension.J Am Heart Assoc · 2020 · PMID 33167773
This page is information, not medical advice. Discuss any trial with your doctor.